AYAL Capital Advisors Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CDMO
Avid Bioservices, Inc. Common Stock
CDMO
|
+$7.22M |
| 2 |
MODV
ModivCare
MODV
|
+$6.78M |
| 3 |
DMC Global
BOOM
|
+$6.46M |
| 4 |
KBR
KBR
|
+$4.95M |
| 5 |
Garrett Motion
GTX
|
+$4.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Charles River Laboratories
CRL
|
+$6.69M |
| 2 |
MasTec
MTZ
|
+$5.8M |
| 3 |
Enviri
NVRI
|
+$5.62M |
| 4 |
Phinia Inc
PHIN
|
+$5.5M |
| 5 |
BERY
Berry Global Group, Inc.
BERY
|
+$5.26M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Industrials | 18.69% |
| 2 | Healthcare | 14.66% |
| 3 | Consumer Discretionary | 11.14% |
| 4 | Utilities | 6.57% |
| 5 | Materials | 5.48% |
Similar funds
AYAL Capital Advisors's Q1 2024 Portfolio in Review
As of Q1 2024, AYAL Capital Advisors held 54 positions worth $227M, down 4.8% from $239M the previous quarter. Its ten largest holdings account for 58% of the portfolio.
AYAL Capital Advisors withdrew a net $28.1M in Q1 2024, closing 20 positions and reducing 6 holdings. Its most notable exit was Charles River Laboratories, an estimated $6.69M position sold in full.
By sector, the portfolio is most concentrated in Industrials at 19% of assets, up from 16% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, AYAL Capital Advisors opened a new position in Avid Bioservices, Inc. Common Stock worth $7.04M.
- AYAL Capital Advisors's largest Q1 2024 buy was Avid Bioservices, Inc. Common Stock: 1,050,000 shares worth $7.04M.
- AYAL Capital Advisors added most to FerroAtlántica in Q1 2024, an estimated $4.43M increase.
- AYAL Capital Advisors's biggest Q1 2024 reduction was Fluor, cutting an estimated $1.99M.
- AYAL Capital Advisors fully exited Charles River Laboratories in Q1 2024, selling an estimated $6.69M.
- AYAL Capital Advisors's ten largest holdings make up 58% of its $227M portfolio in Q1 2024.
- AYAL Capital Advisors opened 18 new positions and closed 20 in Q1 2024.
- AYAL Capital Advisors's portfolio value fell 4.8% quarter-over-quarter to $227M.
Based on AYAL Capital Advisors's 13F filing for Q1 2024, filed 15 May 2024.